Comparing givinostat vs hydroxyurea for polycythemia vera
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polycythemia vera (PV) and have the JAK2 V617F mutation.
- You are 60 years or older, or have had a blood clot in the past 3 years.
- You need treatment because your red blood cell count is high (hematocrit 45% or higher), or you have had a phlebotomy in the last 3 months, or your white blood cell or platelet count is high.
- Your hematocrit must be below 45% at the start of the study.
- You have not been treated with hydroxyurea before, or if you have, you did not have resistance or intolerance to it.
- You do not have serious heart problems, abnormal heart rhythms, or certain other medical conditions listed in the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.